Assenagon Asset Management S.A. Boosts Stake in uniQure (NASDAQ:QURE)

Assenagon Asset Management S.A. boosted its holdings in uniQure (NASDAQ:QURE - Free Report) by 355.2% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 334,894 shares of the biotechnology company's stock after purchasing an additional 261,323 shares during the quarter. Assenagon Asset Management S.A. owned about 0.62% of uniQure worth $3,550,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Avoro Capital Advisors LLC acquired a new stake in shares of uniQure in the 4th quarter valued at about $38,410,000. Franklin Resources Inc. lifted its holdings in uniQure by 33.1% during the fourth quarter. Franklin Resources Inc. now owns 1,987,688 shares of the biotechnology company's stock worth $35,103,000 after acquiring an additional 494,726 shares during the period. Point72 Asset Management L.P. increased its position in shares of uniQure by 81.3% during the 4th quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company's stock valued at $31,282,000 after purchasing an additional 794,459 shares during the last quarter. Integral Health Asset Management LLC increased its holdings in uniQure by 175.0% during the fourth quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company's stock worth $19,426,000 after buying an additional 700,000 shares during the last quarter. Finally, RTW Investments LP raised its holdings in shares of uniQure by 8,936.3% in the 4th quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company's stock worth $15,958,000 after purchasing an additional 893,625 shares during the period. 78.83% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

QURE has been the subject of several analyst reports. Wall Street Zen downgraded uniQure from a "hold" rating to a "sell" rating in a research note on Saturday. Guggenheim reissued a "buy" rating and issued a $28.00 price target on shares of uniQure in a report on Monday, May 12th. HC Wainwright reaffirmed a "buy" rating and set a $70.00 price objective on shares of uniQure in a research note on Thursday, May 29th. Chardan Capital reaffirmed a "buy" rating and set a $38.00 target price on shares of uniQure in a report on Friday, May 30th. Finally, Cantor Fitzgerald raised shares of uniQure to a "strong-buy" rating in a report on Monday, May 19th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, uniQure has a consensus rating of "Moderate Buy" and an average target price of $37.82.

uniQure Trading Down 1.5%

Shares of NASDAQ:QURE traded down $0.23 during trading on Monday, reaching $15.11. 831,959 shares of the company traded hands, compared to its average volume of 1,925,401. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 52-week low of $3.73 and a 52-week high of $19.18. The firm has a market capitalization of $827.67 million, a price-to-earnings ratio of -3.05 and a beta of 0.08. The business's fifty day moving average is $13.59 and its 200-day moving average is $13.65.

uniQure (NASDAQ:QURE - Get Free Report) last announced its quarterly earnings results on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.25. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The business had revenue of $1.57 million during the quarter, compared to analysts' expectations of $5.93 million. As a group, analysts forecast that uniQure will post -3.75 EPS for the current year.

uniQure Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.